To include your compound in the COVID-19 Resource Center, submit it here.

ProQR planning pivotal trial of vision loss candidate

ProQR Therapeutics N.V. (NASDAQ:PRQR) jumped $9.60 (121%) to $17.55 on Wednesday after the company said it plans to start the pivotal Phase II/III ILLUMINATE trial of QR-110 next half to treat Leber congenital

Read the full 330 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE